阿托伐他汀钙片和瑞舒伐他汀哪个效果比较好？
导读：阿托伐他汀钙片的主要成分是阿托伐他汀钙，化学名称为：EP,-(R’，R’)]-2-(4-氟苯基)一B·6一二羟基一5一(1-甲基乙基)一3-苯基-4-[(苯胺)基关]－1－氢一吡咯-1-庚酸钙三水台物。
的主要成分是阿托伐他汀钙，化学名称为：EP,-(R&，R&)]-2-(4-氟苯基)一B&6一二羟基一5一(1-甲基乙基)一3-苯基-4-[(苯胺)基关]－1－氢一吡咯-1-庚酸钙三水台物。
那么，阿托伐他汀钙片和瑞舒伐他汀哪个效果比较好？
阿托伐他汀钙片为他汀类血脂调节药，属HMG-CoA还原酶抑制剂。而舒伐他汀钙片适用于经饮食控制和其它非药物治疗，这两种药对心脑血管疾病的治疗都有一定的帮助。
阿托伐他汀钙片为他汀类血脂调节药，属HMG-CoA还原酶抑制剂。本身无活性，口服吸收后的水解产物在体内竞争性地抑制胆固醇合成过程中的限速酶羟甲戊二酰辅酶A还原酶，使胆固醇的合成减少，也使低密度脂蛋白受体合成增加，主要作用部位在肝脏，结果使血胆固醇和低密度脂蛋白胆固醇水平降低，中度降低血清甘油三酯水平和增高血高密度脂蛋白水平。
瑞舒伐他汀是一种选择性、竞争性的HMG-CoA还原酶抑制剂。HMG-CoA还原酶是3-羟-3-甲戊二酰辅酶A转变成甲羟戊酸过程中的限速酶，甲羟戊酸是胆固醇的前体。动物试验与细胞培养试验结果显示，瑞舒伐他汀被肝脏摄取率高，并具有选择性，肝脏是降低胆固醇的作用靶器官。体内、体外试验结果显示，瑞舒伐他汀能增加细胞表面的肝LDL受体数量，由此增强对LDL的摄取和分解代谢，并抑制肝脏VLDL合成，从而减少VLDL和LDL颗粒的总数量。
相同剂量的阿托伐他汀钙片(立普妥)和(可定)瑞舒伐他汀降低低密度脂蛋白胆固醇的疗效比较而言，瑞舒伐他汀更强一些。但是，瑞舒伐他汀的临床使用时间和经验不如阿托伐他汀多。但在安全性上，阿托伐他汀更好，更让人放心。
为了您的健康，健客网为数万患者提供安全可靠的服务，也积累了丰富的临床经验，因此您尽管把您的皮肤性病科的问题交给我们，我们定当竭诚为您提供专业的治疗方案。欢迎拨打热线电话：400-咨询，我们一定会给您一个满意的答复。
同时还可以登录健客网，进行网上订购，这里我们也有专业的医生为您解答。
（实习编辑：陈惠平）
上一篇：&&&&&&&下一篇：
可能对你有用的产品
相关药品购买
相关治疗医生
相关治疗医院
相关健康经验
健客－国家药监局认证的合法网上药店，致力于打造优质、低价、便捷的网上药店和最值得信赖的智慧健康服务平台
版权所有 Copyright&
All rights reserved关注今日：0 | 主题：415687
微信扫一扫
【资讯翻译】他汀类药物瑞舒伐他汀‘并不配’最畅销药物身份
页码直达：
这个帖子发布于2年零230天前，其中的信息可能已发生改变或有所发展。
【认 领 须 知】<font style="color:#、认领翻译的战友请跟帖注明“认领本文翻译，48小时内未完成，请其他战友认领！”<font style="color:#、请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分<font style="color:#、经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！<font style="color:#、翻译时请参照版规：
5、在首位认领战友未超过规定时间的其他任何认领属违规认领，将不会给予丁当或加分！6、翻译完成后加分（或丁当）的时限为三日，请耐心等待，若超过时限未加者可进行申诉：<font style="color:#、本文题目仅供译者参考，篇幅较长者可申请适当延时8、翻译前请查一下有无重复帖9、为保证翻译质量，每人每天最多只能认领两篇原文链接：/articles/290932.phpStatin drug rosuvastatin 'does not deserve' best-selling slotThe best-selling statin drug, rosuvastatin, which is sold under the Crestor brand, "should not be used," according to a doctor writing in The BMJ - because the evidence of benefit has been weak, and there is growing evidence of side-effects.One of rosuvastatin's licensed uses is to slow the progression of atherosclerosis (narrowing in arteries).Writing as
of the health research arm of the consumer group Public Citizen, Dr. Sidney Wolfe says that he hopes
position as the most prescribed brand name drug in the US in 2014 "declines" - because, says the opinion piece in The BMJ, the evidence of clinical benefit has "fallen" along with "more evidence of risks."Dr. Wolfe suggests that Crestor's annual multibillion dollar success is explained by rosuvastatin having, milligram for milligram, the best cholesterol-lowering potency of all statins - a "fact exploited in advertising campaigns."In spite of its success, the drug should have been withdrawn, the article argues, when Public Citizen first called on the US Food and Drug Administration (FDA) to consider "serious problems [that] were identified before rosuvastatin's [FDA] approval."Dr. Wolfe expresses his exasperation at the persistent use of the statin brand, which is licensed for prevention of
as well as to lower high
levels.He asks: "Given the evidence of more serious risks and less clinical benefit than other statins, how has the drug fared so well for so long?"The FDA license for Crestor specifies preventive prescribing for "slowing the progression of " in addition to treating primary hyperlipidemia and other disorders of cholesterol levels. In the US in 2014, some 22.3 million prescriptions were filled for the drug.The
in late 2010 to include further preventive use, but this "later approval to prevent
in a very selected group of people was based on the results of a study which was stopped early," says The BMJin a press release, "prompting concern that the treatment effects may have been overestimated.""There is also growing evidence that the drug carries a higher risk of serious adverse effects compared with other statins, such as an increased risk of developing ."Marketing campaigns in the 'statins war'Dr. Wolfe believes safety concerns have not been taken into account in marketing activities for the drug amid a so-called statins war.He describes a row that played out in another leading medical journal, The Lancet, about whether AstraZeneca, the pharmaceutical company responsible for Crestor, "pushed its marketing machine too hard and too fast."That editorial was in 2003, and Dr Wolfe goes on to cite a 2004 warning from the FDA against AstraZeneca's marketing - specifically, a clarification about the accuracy of an advert that the company took out in response to Public Citizen's campaign against the drug, he says.The FDA was concerned on that occasion about how far the company claimed its statin was safer than the other drugs in the class, and later warned the company again, writes Dr. Wolfe, about the way it made a claim in other promotions for the comparative efficacy of Crestor.Dr. Wolfe concludes his argument against rosuvastatin by saying he hopes "the drug's disadvantages will lead to a sharp decline in its use" before the AstraZeneca patent for rosuvastatin expires in 2016.He worries that, without the points he raises being widely heard, the drug could continue to enjoy success in the same way that other statin drugs have done so after coming off patent. Dr. Wolfe says:"When patents expired for simvastatin, pravastatin and , the rise in generic prescriptions quickly equaled or exceeded the sharp decreases in brand name prescriptions."Dr. Wolfe ends The BMJ's feature article by hoping that because "AstraZeneca's need to promote" the drug would stop in 2016 with the patent loss, the campaign against rosuvastatin would have an effect "for the sake of the public's health."MNT asked a spokesperson for AstraZeneca to respond to Dr. Wolfe's article. The company said: "Crestor is an effective treatment for lowering LDL-cholesterol and raising HDL-cholesterol, when compared to other statins, and it has been shown to slow the progression of atherosclerosis."The company added that it took its commitment to patient safety "extremely seriously" and that Crestor "has a well-established safety profile." AstraZeneca also responded that Crestor "is approved by health care authorities in over 109 countries and used by tens of millions of patients worldwide."In other news about cholesterol-lowering drugs this week, a new type of treatment, a monoclonal antibody, . The drug, , has been submitted to the FDA and UK and EU regulators in application for marketing licenses.
不知道邀请谁？试试他们
微信扫一扫
广告宣传推广
政治敏感、违法虚假信息
恶意灌水、重复发帖
违规侵权、站友争执
附件异常、链接失效
收起全部有料回复
丁香园准中级站友
此次翻译感觉有点吃力，肯定有很多不当之处，请大家多多多指导。
初译：<font style="color:#、Statin drug rosuvastatin 'does not deserve' best-selling slot他汀类药物瑞舒伐他汀‘并不配’最畅销药物身份2、The best-selling statin drug, rosuvastatin, which is sold under the Crestor brand, "should not be used," according to a doctor writing in The BMJ - because the evidence of benefit has been weak, and there is growing evidence of side-effects.根据一位医生发表在《英国医学杂志》上的文章称，以Crestor商品名出售的最畅销他汀类药物-瑞舒伐他汀，由于有关其治疗效益（持续）薄弱，而有关其副作用证据不断涌现，不应该再被继续使用。3、One of rosuvastatin's licensed uses is to slow the progression of atherosclerosis (narrowing in arteries).瑞舒伐他汀其中一项被许可的用途是用于减缓动脉粥样硬化（动脉狭窄）的发展进程。4、Writing as founder of the health research arm of the consumer group Public Citizen, Dr. Sidney Wolfe says that he hopes Crestor's position as the most prescribed brand name drug in the US in 2014 "declines" - because, says the opinion piece in The BMJ, the evidence of clinical benefit has "fallen" along with "more evidence of risks."正如公共市民消费者团体的医疗研究机构创始人Sidney Wolfe博士说的，他希望Crestor作为美国2014最畅销的预防药物品牌的地位能够下降，因为正如《英国医学杂志》的一篇文章中的观点那样，有关的临床效益证据不断降低以及与其风险相关的证据不断涌现。<font style="color:#、Dr. Wolfe suggests that Crestor's annual multibillion dollar success is explained by rosuvastatin having, milligram for milligram, the best cholesterol-lowering potency of all statins - a "fact exploited in advertising campaigns."Wolfe博士声称，Crestor每年数十亿的成功收入是由于广告中宣称上网瑞舒伐他汀在他汀类药物中拥有按每毫克最好的降低胆固醇的能力。<font style="color:#、In spite of its success, the drug should have been withdrawn, the article argues, when Public Citizen first called on the US Food and Drug Administration (FDA) to consider "serious problems [that] were identified before rosuvastatin's [FDA] approval."文章认为，瑞舒伐他汀尽管销售上很成功，但它早就应该下架了。事实上，在它获批之前“公民”论坛率先呼吁美国食品药品监督管理局（FDA）不要忽视该药的严重问题时，这些问题就得到了确认。<font style="color:#、Dr. Wolfe expresses his exasperation at the persistent use of the statin brand, which is licensed for prevention of
as well as to lower high
levels.Wolfe博士在‘依旧在持续不断的使用这个他汀类药物’这个问题上表达了愤怒。该他汀类品牌适应症是预防心脏疾病、中风以及降低高胆固醇水平。<font style="color:#、He asks: "Given the evidence of more serious risks and less clinical benefit than other statins, how has the drug fared so well for so long?"他质问道：“考虑到与其他的他汀类药物相比，（瑞舒伐他汀）出现更多严重的风险证据以及更低的临床效益，它是如何做到能够如此长时间的获得收益？”<font style="color:#、The FDA license for Crestor specifies preventive prescribing for "slowing the progression of atherosclerosis" in addition to treating primary hyperlipidemia and other disorders of cholesterol levels. In the US in 2014, some 22.3 million prescriptions were filled for the drug.FDA批准Crestor除治疗原发性高脂血症以及其他的胆固醇水平紊乱外，还可作为预防性处方药用来减缓动脉粥样硬化进程。2014年，美国大约有2230万处方中有这种药物。<font style="color:#、The FDA license was updated in late 2010 to include further preventive use, but this "later approval to prevent heart attacks in a very selected group of people was based on the results of a study which was stopped early," says The BMJin a press release, "prompting concern that the treatment effects may have been overestimated."美国FDA的许可是在2010年年底更新，包括进一步的预防性使用，但是英国医学杂志综合报道称：后来批准的关于防止在一个特异性的群体中预防心脏病，是基于一项提前终止的研究的结果，这引起了人们对其治疗效果可能被高估的担心。<font style="color:#、"There is also growing evidence that the drug carries a higher risk of serious adverse effects compared with other statins, such as an increased risk of developing diabetes."越来越多的证据表明。与其他他汀类药物相比，该药物带有更高的发生严重副作用的风险，比如说患糖尿病的风险不断升高。<font style="color:#、Marketing campaigns in the 'statins war'他汀类战争中的营销活动<font style="color:#、Dr. Wolfe believes safety concerns have not been taken into account in marketing activities for the drug amid a so-called statins war。Wolfe博士认为在所谓的他汀类药物战争中，在营销活动中并没有考虑到安全问题。<font style="color:#、He describes a row that played out in another leading medical journal, The Lancet, about whether AstraZeneca, the pharmaceutical company responsible for Crestor, "pushed its marketing machine too hard and too fast."他描述了在另一个顶尖医学杂志-《柳叶刀》中发生的一场争论，即Crestor生产商阿斯利康是否对Crestor营销机器开的太快太努力负责。<font style="color:#、That editorial was in 2003, and Dr Wolfe goes on to cite a 2004 warning from the FDA against AstraZeneca's marketing - specifically, a clarification about the accuracy of an advert that the company took out in response to Public Citizen's campaign against the drug, he says.那篇编辑部社论发表于2003年，Wolfe博士继续列举了阿斯利康在2004年收到的FDA关于营销活动的警告。他说，该公司为应对公共市民组织抵抗该药物的活动，该公司专门对广告的精确度做出澄清。<font style="color:#、The FDA was concerned on that occasion about how far the company claimed its statin was safer than the other drugs in the class, and later warned the company again, writes Dr. Wolfe, about the way it made a claim in other promotions for the comparative efficacy of Crestor.Wolfe博士写到，在那个时候FDA关注的是该公司宣称的它的他汀类药物比其他同类药物更加安全的程度并且不久又警告了这家公司关于在其它促销活动中对Crestor的比较疗效的宣传方式。<font style="color:#、Dr. Wolfe concludes his argument against rosuvastatin by saying he hopes "the drug's disadvantages will lead to a sharp decline in its use" before the AstraZeneca patent for rosuvastatin expires in 2016.Wolfe博士用它的期望总结了对瑞舒伐他汀的批评，他希望该药物在2016年阿斯利康对瑞舒伐他汀的专利保护到期之前，可以因为它的缺点而导致其使用量急速下降。<font style="color:#、He worries that, without the points he raises being widely heard, the drug could continue to enjoy success in the same way that other statin drugs have done so after coming off patent. 他担心，如果他提出的观点没有被广泛听取，该药物在采取与其他的到期专利药物相同的方法后，可以继续享受巨大的成功。<font style="color:#、Dr. Wolfe says:"When patents expired for simvastatin, pravastatin and atorvastatin, the rise in generic prescriptions quickly equaled or exceeded the sharp decreases in brand name prescriptions."Wolfe博士，说：““当辛伐他汀，普伐他汀和阿托伐他汀专利过期，一般的处方销量迅速等于或超过急剧下跌的名药的处方。”<font style="color:#、Dr. Wolfe ends The BMJ's feature article by hoping that because "AstraZeneca's need to promote" the drug would stop in 2016 with the patent loss, the campaign against rosuvastatin would have an effect "for the sake of the public's health."Wolfe博士在BMJ的专题文章以其期望结尾：希望阿斯利康的专利将在2016年结束，与瑞舒伐他汀的这场战役将会在寻求公众安全这方面有一个影响。<font style="color:#、MNT asked a spokesperson for AstraZeneca to respond to Dr. Wolfe's article. The company said: "Crestor is an effective treatment for lowering LDL-cholesterol and raising HDL-cholesterol, when compared to other statins, and it has been shown to slow the progression of atherosclerosis."MNT询问阿斯利康的发言人针对Wolfe博士文章的反应。发言人说道：“与其他他汀类药物相比，Crestor是一项针对降低低密度脂蛋白-胆固醇水平和升高高密度脂蛋白-胆固醇水平有效的治疗手段，已有证据显示它可以减缓动脉粥样硬化的进程。<font style="color:#、The company added that it took its commitment to patient safety "extremely seriously" and that Crestor "has a well-established safety profile." AstraZeneca also responded that Crestor "is approved by health care authorities in over 109 countries and used by tens of millions of patients worldwide."该公司补充说，它非常严肃的履行了它对于患者安全的承诺，并且Crestor“拥有完善评估的安全性。”阿斯利康也回应称Crestor“被超过109个国家的保健当局批准和全球数以百万计的患者使用。”<font style="color:#、In other news about cholesterol-lowering drugs this week, a new type of treatment, a monoclonal antibody, could be more effective than statins. The drug, evolocumab, has been submitted to the FDA and UK and EU regulators in application for marketing licenses.在本周关于降胆固醇药物的报道中，一种单克隆抗体比他汀类药物更加有效。一种被称为evolocumab的药物已经提交给FDA以及英国和欧洲的监管机构，申请运营牌照。
微信扫一扫
广告宣传推广
政治敏感、违法虚假信息
恶意灌水、重复发帖
违规侵权、站友争执
附件异常、链接失效
捣麝成尘 编辑于
丁香园准中级站友
认领本文翻译，48小时内未完成，请其他战友认领！
微信扫一扫
广告宣传推广
政治敏感、违法虚假信息
恶意灌水、重复发帖
违规侵权、站友争执
附件异常、链接失效
丁香园准中级站友
此次翻译感觉有点吃力，肯定有很多不当之处，请大家多多多指导。
初译：<font style="color:#、Statin drug rosuvastatin 'does not deserve' best-selling slot他汀类药物瑞舒伐他汀‘并不配’最畅销药物身份2、The best-selling statin drug, rosuvastatin, which is sold under the Crestor brand, "should not be used," according to a doctor writing in The BMJ - because the evidence of benefit has been weak, and there is growing evidence of side-effects.根据一位医生发表在《英国医学杂志》上的文章称，以Crestor商品名出售的最畅销他汀类药物-瑞舒伐他汀，由于有关其治疗效益（持续）薄弱，而有关其副作用证据不断涌现，不应该再被继续使用。3、One of rosuvastatin's licensed uses is to slow the progression of atherosclerosis (narrowing in arteries).瑞舒伐他汀其中一项被许可的用途是用于减缓动脉粥样硬化（动脉狭窄）的发展进程。4、Writing as founder of the health research arm of the consumer group Public Citizen, Dr. Sidney Wolfe says that he hopes Crestor's position as the most prescribed brand name drug in the US in 2014 "declines" - because, says the opinion piece in The BMJ, the evidence of clinical benefit has "fallen" along with "more evidence of risks."正如公共市民消费者团体的医疗研究机构创始人Sidney Wolfe博士说的，他希望Crestor作为美国2014最畅销的预防药物品牌的地位能够下降，因为正如《英国医学杂志》的一篇文章中的观点那样，有关的临床效益证据不断降低以及与其风险相关的证据不断涌现。<font style="color:#、Dr. Wolfe suggests that Crestor's annual multibillion dollar success is explained by rosuvastatin having, milligram for milligram, the best cholesterol-lowering potency of all statins - a "fact exploited in advertising campaigns."Wolfe博士声称，Crestor每年数十亿的成功收入是由于广告中宣称上网瑞舒伐他汀在他汀类药物中拥有按每毫克最好的降低胆固醇的能力。<font style="color:#、In spite of its success, the drug should have been withdrawn, the article argues, when Public Citizen first called on the US Food and Drug Administration (FDA) to consider "serious problems [that] were identified before rosuvastatin's [FDA] approval."文章认为，瑞舒伐他汀尽管销售上很成功，但它早就应该下架了。事实上，在它获批之前“公民”论坛率先呼吁美国食品药品监督管理局（FDA）不要忽视该药的严重问题时，这些问题就得到了确认。<font style="color:#、Dr. Wolfe expresses his exasperation at the persistent use of the statin brand, which is licensed for prevention of
as well as to lower high
levels.Wolfe博士在‘依旧在持续不断的使用这个他汀类药物’这个问题上表达了愤怒。该他汀类品牌适应症是预防心脏疾病、中风以及降低高胆固醇水平。<font style="color:#、He asks: "Given the evidence of more serious risks and less clinical benefit than other statins, how has the drug fared so well for so long?"他质问道：“考虑到与其他的他汀类药物相比，（瑞舒伐他汀）出现更多严重的风险证据以及更低的临床效益，它是如何做到能够如此长时间的获得收益？”<font style="color:#、The FDA license for Crestor specifies preventive prescribing for "slowing the progression of atherosclerosis" in addition to treating primary hyperlipidemia and other disorders of cholesterol levels. In the US in 2014, some 22.3 million prescriptions were filled for the drug.FDA批准Crestor除治疗原发性高脂血症以及其他的胆固醇水平紊乱外，还可作为预防性处方药用来减缓动脉粥样硬化进程。2014年，美国大约有2230万处方中有这种药物。<font style="color:#、The FDA license was updated in late 2010 to include further preventive use, but this "later approval to prevent heart attacks in a very selected group of people was based on the results of a study which was stopped early," says The BMJin a press release, "prompting concern that the treatment effects may have been overestimated."美国FDA的许可是在2010年年底更新，包括进一步的预防性使用，但是英国医学杂志综合报道称：后来批准的关于防止在一个特异性的群体中预防心脏病，是基于一项提前终止的研究的结果，这引起了人们对其治疗效果可能被高估的担心。<font style="color:#、"There is also growing evidence that the drug carries a higher risk of serious adverse effects compared with other statins, such as an increased risk of developing diabetes."越来越多的证据表明。与其他他汀类药物相比，该药物带有更高的发生严重副作用的风险，比如说患糖尿病的风险不断升高。<font style="color:#、Marketing campaigns in the 'statins war'他汀类战争中的营销活动<font style="color:#、Dr. Wolfe believes safety concerns have not been taken into account in marketing activities for the drug amid a so-called statins war。Wolfe博士认为在所谓的他汀类药物战争中，在营销活动中并没有考虑到安全问题。<font style="color:#、He describes a row that played out in another leading medical journal, The Lancet, about whether AstraZeneca, the pharmaceutical company responsible for Crestor, "pushed its marketing machine too hard and too fast."他描述了在另一个顶尖医学杂志-《柳叶刀》中发生的一场争论，即Crestor生产商阿斯利康是否对Crestor营销机器开的太快太努力负责。<font style="color:#、That editorial was in 2003, and Dr Wolfe goes on to cite a 2004 warning from the FDA against AstraZeneca's marketing - specifically, a clarification about the accuracy of an advert that the company took out in response to Public Citizen's campaign against the drug, he says.那篇编辑部社论发表于2003年，Wolfe博士继续列举了阿斯利康在2004年收到的FDA关于营销活动的警告。他说，该公司为应对公共市民组织抵抗该药物的活动，该公司专门对广告的精确度做出澄清。<font style="color:#、The FDA was concerned on that occasion about how far the company claimed its statin was safer than the other drugs in the class, and later warned the company again, writes Dr. Wolfe, about the way it made a claim in other promotions for the comparative efficacy of Crestor.Wolfe博士写到，在那个时候FDA关注的是该公司宣称的它的他汀类药物比其他同类药物更加安全的程度并且不久又警告了这家公司关于在其它促销活动中对Crestor的比较疗效的宣传方式。<font style="color:#、Dr. Wolfe concludes his argument against rosuvastatin by saying he hopes "the drug's disadvantages will lead to a sharp decline in its use" before the AstraZeneca patent for rosuvastatin expires in 2016.Wolfe博士用它的期望总结了对瑞舒伐他汀的批评，他希望该药物在2016年阿斯利康对瑞舒伐他汀的专利保护到期之前，可以因为它的缺点而导致其使用量急速下降。<font style="color:#、He worries that, without the points he raises being widely heard, the drug could continue to enjoy success in the same way that other statin drugs have done so after coming off patent. 他担心，如果他提出的观点没有被广泛听取，该药物在采取与其他的到期专利药物相同的方法后，可以继续享受巨大的成功。<font style="color:#、Dr. Wolfe says:"When patents expired for simvastatin, pravastatin and atorvastatin, the rise in generic prescriptions quickly equaled or exceeded the sharp decreases in brand name prescriptions."Wolfe博士，说：““当辛伐他汀，普伐他汀和阿托伐他汀专利过期，一般的处方销量迅速等于或超过急剧下跌的名药的处方。”<font style="color:#、Dr. Wolfe ends The BMJ's feature article by hoping that because "AstraZeneca's need to promote" the drug would stop in 2016 with the patent loss, the campaign against rosuvastatin would have an effect "for the sake of the public's health."Wolfe博士在BMJ的专题文章以其期望结尾：希望阿斯利康的专利将在2016年结束，与瑞舒伐他汀的这场战役将会在寻求公众安全这方面有一个影响。<font style="color:#、MNT asked a spokesperson for AstraZeneca to respond to Dr. Wolfe's article. The company said: "Crestor is an effective treatment for lowering LDL-cholesterol and raising HDL-cholesterol, when compared to other statins, and it has been shown to slow the progression of atherosclerosis."MNT询问阿斯利康的发言人针对Wolfe博士文章的反应。发言人说道：“与其他他汀类药物相比，Crestor是一项针对降低低密度脂蛋白-胆固醇水平和升高高密度脂蛋白-胆固醇水平有效的治疗手段，已有证据显示它可以减缓动脉粥样硬化的进程。<font style="color:#、The company added that it took its commitment to patient safety "extremely seriously" and that Crestor "has a well-established safety profile." AstraZeneca also responded that Crestor "is approved by health care authorities in over 109 countries and used by tens of millions of patients worldwide."该公司补充说，它非常严肃的履行了它对于患者安全的承诺，并且Crestor“拥有完善评估的安全性。”阿斯利康也回应称Crestor“被超过109个国家的保健当局批准和全球数以百万计的患者使用。”<font style="color:#、In other news about cholesterol-lowering drugs this week, a new type of treatment, a monoclonal antibody, could be more effective than statins. The drug, evolocumab, has been submitted to the FDA and UK and EU regulators in application for marketing licenses.在本周关于降胆固醇药物的报道中，一种单克隆抗体比他汀类药物更加有效。一种被称为evolocumab的药物已经提交给FDA以及英国和欧洲的监管机构，申请运营牌照。
微信扫一扫
广告宣传推广
政治敏感、违法虚假信息
恶意灌水、重复发帖
违规侵权、站友争执
附件异常、链接失效
捣麝成尘 编辑于
关于丁香园